Page 37 - ARNM-3-3

Advances in Radiotherapy
& Nuclear Medicine Brachytherapy versus external beam in local dose escalation

Cancer in the oropharynx: Cost calculation of different analysis. J Contemp Brachytherapy. 2019;11(1):21-27.
treatment modalities for controlled primaries, relapses and
grade III/IV complications. Radiother Oncol. 2005;77(1):65-72. doi: 10.5114/jcb.2019.82804
32. Kent C, Bessell EM, Scholefield JH, et al. Chemoradiotherapy
doi: 10.1016/j.radonc.2005.09.007
with brachytherapy or electron therapy boost for locally
29. Budrukkar A, Murthy V, Kashid S, et al. Intensity-modulated advanced squamous cell carcinoma of the anus-reducing the
radiation therapy alone versus intensity-modulated radiation colostomy rate. J Gastrointest Cancer. 2017;48(1):1-7.
therapy and brachytherapy for early-stage oropharyngeal
cancers: Results from a randomized controlled trial. Int J doi: 10.1007/s12029-016-9850-4
Radiat Oncol Biol Phys. 2024;118(5):1541-1551. 33. Moureau-Zabotto L, Ortholan C, Hannoun-Levi JM, et al.
doi: 10.1016/j.ijrobp.2023.08.056 Role of brachytherapy in the boost management of anal
carcinoma with node involvement (CORS-03 study). Int J
30. Oehler-Jänne C, Seifert B, Lütolf UM, Studer G, Radiat Oncol Biol Phys. 2013;85(3):e135-e142.
Glanzmann C, Ciernik IF. Clinical outcome after treatment
with a brachytherapy boost versus external beam boost for doi: 10.1016/j.ijrobp.2012.09.034
anal carcinoma. Brachytherapy. 2007;6(3):218-226. 34. Allal AS, Mermillod B, Roth AD, Marti MC, Kurtz JM.
doi: 10.1016/j.brachy.2007.02.152 The impact of treatment factors on local control in T2-T3
anal carcinomas treated by radiotherapy with or without
31. Arcelli A, Buwenge M, Macchia G, et al. Long-term results of
chemoradiation plus pulsed-dose-rate brachytherapy boost chemotherapy. Cancer. 1997;79(12):2329-2335.
in anal canal carcinoma: A mono-institutional retrospective doi: 10.1002/(sici)1097-0142(19970615)

Volume 3 Issue 3 (2025) 29 doi: 10.36922/ARNM025160017